Susan Mahony
CIK: 0001463321
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Jun 10, 2026AXSM
Axsome Therapeutics, Inc.
Sale(S)Direct300 shares at avg. $246.18$74K - Jun 9, 2026AXSM
Axsome Therapeutics, Inc.
Sale(S)Direct300 shares at avg. $237.21$71K - Jun 8, 2026AXSM
Axsome Therapeutics, Inc.
Exercise(M)Direct1.4K shares- - Jun 5, 2026AXSM
Axsome Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
1.7K shares- - Jun 4, 2026ASMB
ASSEMBLY BIOSCIENCES, INC.
Award(A)DirectStock Option (right to buy)
8K shares- - Jan 12, 2026ZYME
Zymeworks Inc.
Award(A)DirectRestricted Stock Unit
7.7K shares- - Jan 12, 2026ZYME
Zymeworks Inc.
Award(A)DirectStock Option (Right to Buy)
11.5K shares- - Jun 6, 2025AXSM
Axsome Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
1.4K shares- - Jun 6, 2025AXSM
Axsome Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
3.2K shares- - Jun 5, 2025ASMB
ASSEMBLY BIOSCIENCES, INC.
Award(A)DirectStock Option (right to buy)
3.5K shares- - Feb 21, 2025AXSM
Axsome Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
1.3K shares- - Dec 10, 2024ZYME
Zymeworks Inc.
Award(A)DirectStock Option (Right to Buy)
31K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 10, 2026 |  AXSM Axsome Therapeutics, Inc. | Sale(S) | 300 | $246.18 | $73,854 | Direct |
| Jun 9, 2026 | AXSM Axsome Therapeutics, Inc. | Sale(S) | 300 | $237.21 | $71,163 | Direct |
| Jun 8, 2026 | AXSM Axsome Therapeutics, Inc. | Exercise(M) | 1,429 | - | $0 | Direct |
| Jun 5, 2026 | AXSM Axsome Therapeutics, Inc. | Award(A) Restricted Stock Units | 1,721 | - | - | Direct |
| Jun 4, 2026 |  ASMB ASSEMBLY BIOSCIENCES, INC. | Award(A) Stock Option (right to buy) | 8,000 | - | - | Direct |
| Jan 12, 2026 |  ZYME Zymeworks Inc. | Award(A) Restricted Stock Unit | 7,700 | - | - | Direct |
| Jan 12, 2026 | ZYME Zymeworks Inc. | Award(A) Stock Option (Right to Buy) | 11,500 | - | - | Direct |
| Jun 6, 2025 | AXSM Axsome Therapeutics, Inc. | Award(A) Restricted Stock Units | 1,429 | - | - | Direct |
| Jun 6, 2025 | AXSM Axsome Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 3,166 | - | - | Direct |
| Jun 5, 2025 | ASMB ASSEMBLY BIOSCIENCES, INC. | Award(A) Stock Option (right to buy) | 3,500 | - | - | Direct |
| Feb 21, 2025 | AXSM Axsome Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 1,312 | - | - | Direct |
| Dec 10, 2024 | ZYME Zymeworks Inc. | Award(A) Stock Option (Right to Buy) | 31,000 | - | - | Direct |
1-12 of 12 transactions
About Mahony Susan
Mahony Susan (SEC CIK 0001463321) files insider reports with the SEC as Director of Axsome Therapeutics, Inc. (AXSM), Director of ASSEMBLY BIOSCIENCES, INC. (ASMB) and Director of Zymeworks Inc. (ZYME).
Signal8 holds 8 ownership filings by Mahony Susan, all Form 4s, filed between Dec 12, 2024 and Jun 10, 2026. Those filings report 12 transactions, from Dec 10, 2024 to Jun 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Mahony Susan's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Mahony Susan
- Jun 10, 2026: Open-market sale of AXSM shares (Form 4, code S).
- Jun 9, 2026: Open-market sale of AXSM shares (Form 4, code S).
- Jun 8, 2026: Option exercise of AXSM shares (Form 4, code M).
- Jun 5, 2026: Grant or award of AXSM derivative securities (Form 4, code A).
- Jun 4, 2026: Grant or award of ASMB derivative securities (Form 4, code A).
Other insiders filing for Axsome Therapeutics, Inc. (AXSM)
- Jacobson Mark L., Chief Operating Officer
- TABUTEAU HERRIOT, Chief Executive Officer
- JEFFS ROGER, Director
- Saad Mark E, Director
- Coleman Mark, Director
- Pizzie Nick, Chief Financial Officer